Foundation Medicine (NASDAQ:FMI)

CAPS Rating: 4 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar OklaBoston (68.01) Submitted: 11/29/2014 2:29:22 PM : Underperform Start Price: $23.46 FMI Score: -2.54

Not worth more than $17.00 despite good Q/Q numbers.

Recs

0
Member Avatar Turtlebale (62.17) Submitted: 10/28/2014 3:19:23 PM : Outperform Start Price: $27.54 FMI Score: -16.88

first mover platform; will win in market or get acquired on the way

Recs

0
Member Avatar waynehe (86.21) Submitted: 9/8/2014 9:53:33 AM : Outperform Start Price: $22.20 FMI Score: +5.76

first mover adv.

Recs

0
Member Avatar TMFInnovator (42.90) Submitted: 9/3/2014 3:29:11 PM : Outperform Start Price: $22.88 FMI Score: +2.15

Foundation Medicine runs high-speed genomic tests to profile individual patients, identify genetic abnormalities, and then recommend the best course of action for their treatment. I expect them to benefit from continued adoption of personalized medicine.

Growth - FMI saw a 263% increase in the number of their tests ordered by oncologists yr/yr. The growth is becoming more diversified - with less from biopharmaceutical companies (of which they now have 18 partners, including JNJ, Sanofi, and Novartis) and more directly from doctors' offices. This, to me, signifies a move to more mass-market adoption.

Platform - Foundation has a database of 21,000 patient case studies. As the first-mover in this space, they'll optimize that with each new data point -- further improving decisions and outcomes.

Value Proposition - Physicians changed their therapeutic decision in 28% of cases studied after reviewing FMI's identification of genetic alterations. Their data is valuable.

Smart Money - FMI is backed by some big name VCs, such as ThirdRock (who owns 18%), Kleiner Perkins (10%), and Google Ventures (4%). These are ambitious, long-term-minded investors.

The Wild Card - I expect Medicare reimbursements to warm up to genomic testing in the future (especially as the prices come down). That could be a serious catalyst to FMI's stock price.

Foundation is a risky pick, but I think they're worth it. Outperform.

Recs

0
Member Avatar Astokian (< 20) Submitted: 6/16/2014 12:30:56 PM : Outperform Start Price: $22.69 FMI Score: -0.35

The technology will find a use with a growing base of users

Recs

0
Member Avatar GVFool15 (71.93) Submitted: 2/10/2014 10:06:07 PM : Outperform Start Price: $30.12 FMI Score: -34.72

If it's good enough for Google Ventures to be investing in, it's good enough for me. This pick is for fun!

Recs

0
Member Avatar usubanas (99.70) Submitted: 1/17/2014 3:11:08 PM : Outperform Start Price: $30.44 FMI Score: -33.40

The future is... here

Recs

0
Member Avatar NiksurfsInvestmt (26.14) Submitted: 12/25/2013 11:19:09 PM : Outperform Start Price: $25.98 FMI Score: -21.85

This could be the surprise of 2014. I believe it will get added to Medicare funding and Insurance Companies dockets, once that happens revenue and earnings will take off and so will this stock. Stay tuned………………….

Results 1 - 8 of 8

Featured Broker Partners


Advertisement